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Background: Definitive chemoradiotherapy (CRT) is the primary treatment for
non-metastatic anal squamous cell carcinoma (ASCC). Despite favorable treatment
outcomes in general, failure rates up to 40% occur in locally advanced disease. For
treatment escalation or de-escalation strategies easily assessable and valid biomarkers
are needed.
Methods: We identified 125 patients with ASCC treated with standard CRT at our
department. C-reactive protein (CRP) to albumin ratio (CAR) was calculated dividing
baseline CRP by baseline albumin levels. We used maximally selected rank statistics
to dichotomize patients to high and low risk groups. Associations of CAR with
clinicopathologic parameters were evaluated and the prognostic impact was tested
using univariate and multivariate cox regression analysis. In a subset of 78 patients,
pretreatment tumor tissue was available and CD8+ tumor infiltrating lymphocytes (TILs)
and p16INK4a status were scored by immunohistochemistry and correlated with CAR.
Results: Advanced T-stage and male gender were significantly associated with higher
baseline CAR. Using the calculated cutoff of 0.117, a high baseline CAR was also
associated with worse locoregional control (p = 0.002), distant metastasis-free survival
(p = 0.01), disease-free survival (DFS, p = 0.002) and overall survival (OS, p < 0.001).
A combined risk score incorporating N-stage and CAR, termed N-CAR score, was
associated with worse outcome across all endpoints and in multivariate analysis
independent of T-stage and Gender (HR 4.27, p = 0.003). In the subset of 78 patients,
a strong infiltration with intratumoral CD8+ TIL was associated with a significantly lower
CAR (p= 0.007). CAR is an easily accessible biomarker that is associated with DFS. Our
study revealed a possible link between chronic systemic inflammation and an impaired
intratumoral immune response.
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INTRODUCTION
Anal squamous cell carcinoma (ASCC) is characterized
by increasing incidence in developed countries (1, 2).
Chemoradiotherapy (CRT) is the primary treatment for
non-metastatic disease (3). In general, treatment outcomes
are favorable but relapse occurs in up to 40% of patients with
advanced stages (cT3-4 and/or cN+) (3, 4). Pretreatment
biomarkers that can be obtained easily are needed to select
patients for treatment escalation strategies. Conversely, as CRT
can be associated with substantial long-term gastrointestinal
toxicities (5), there is a need for de-escalation strategies to avoid
overtreatment in patients with favorable prognosis. Randomized
trials have established prognostic clinical factors like T-stage,
N-stage and gender (6, 7). More recently, human papilloma
virus (HPV)/p16INK4a status and infiltration with CD8+ tumor
infiltrating lymphocytes (TIL) have been validated as prognostic
molecular markers (8–11).
The role of the immune system for cancer progression
has been elucidated in recent decades. The prognostic impact
of inflammation-associated blood cells, like leukocytes or
neutrophils, has been reported in ASCC (12–14) and other
malignancies (15, 16). C-reactive protein (CRP) is an acute
phase protein, secreted by the liver upon interleukin 6
(IL-6) stimulation, and physiologically acts as part of the
complement system (17). Clinically, CRP is used mainly as a
marker for inflammation. Patients with colorectal cancer display
significantly elevated baseline CRP levels as compared to healthy
individuals (18).
Serum albumin levels can be an indicator of malnutrition that
in turn is associated with impaired immune response in cancer
patients (19). Due to their close link, the ratio of CRP to albumin
(CAR) has been proposed as a marker to identify patients at risk
for early mortality from sepsis (20). Moreover, high baseline CAR
values have been associated with worse prognosis in head and
neck squamous cell, bladder, esophageal cancer, and others (21–
24), but have not been evaluated in ASCC yet. In the present
study, we aimed to investigate the correlation of CAR with
established clinical (T/N-stage, gender) andmolecular prognostic
factors (CD8+ TIL, p16INK4a) and analyze its prognostic value
in patients with ASCC treated with standard definitive CRT.
MATERIALS/METHODS
Patients and Treatment Protocol
We identified 126 patients with histologically confirmed,
non-metastatic ASCC treated between 12/2004 and 12/2016
with definitive CRT at our department. Written consent and
approval from the institutional review board and patients was
obtained. Patients were routinely staged by physical and rectal-
digital examination, proctoscopy with biopsy, CT or MRI of
the abdomen and pelvis, chest X-ray, serum chemistry, and
complete blood count. TNM staging was done according to the
UICC version 7.
Radiotherapy was applied using either 3D-conformal
radiotherapy (RT) or intensity-modulated-RT (IMRT). Patients
were treated with amedian total dose of 59.4 Gray (Gy) with daily
fractions of 1.8 or 2Gy. Chemotherapy was applied in the first
and fifth week of radiotherapy and consisted of 5-fluorouracil
(1,000 mg/m2/day or 800 mg/m2/day) as 4 or 5 day continuous
infusion and mitomycin C (MMC) given as an intravenous bolus
(10 mg/m2) on day 1 of each cycle.
Response Assessment and Follow-Up
Initial response assessment was scheduled 8–10 weeks after
completion of CRT and every 3 months afterwards for
the first 2 years, followed by 6 month intervals thereafter.
Examination included physical and digital rectal examination,
proctoscopy (with biopsies in case of suspicious lesions) and
pelvic CT/MRI scan.
Serum Chemistry
We collected the baseline CRP and albumin values from our
hospital database. Blood samples were collected as part of routine
test battery before application of chemotherapy. Baseline was
defined as either the day of treatment initiation or up to 4 days
before. CAR was calculated by dividing CRP in mg/dl through
albumin in g/dl.
Immunohistochemistry for CD8 TIL and
p16INK4a
In a subset of 78 patients formalin fixed paraffin embedded
(FFPE) pretreatment tumor tissue was available and
immunohistochemical staining of CD8 TIL and p16INK4a
was performed by a horseradish-peroxidase technique using a
DAKO Autostainer Link 48 (DAKO, Hamburg, Germany) with
standardized Dako EnVision
TM
FLEX Blocking reagent (K800,
DAKO), CD8 antibody (1:100, clone C8/144B; Dako M7103)
and a CINtec histology kit (Roche, Heidelberg, Germany)
for p16INK4a. Next, dextran polymer conjugated horseradish-
peroxidase and 3,3’-diaminobenzidine (DAB) chromogen was
used for visualization and hematoxylin solution (Gill 3, Sigma
Aldrich, Munich, Germany) for counterstaining. Negative
control slides in the absence of primary antibodies were included
for each staining. The scoring of expression of CD8+ TIL was
done semi-quantitatively as described before (8). Categories for
scoring were: (1) no, or sporadic cells; (2) moderate number
of cells; (3) abundant occurrence of cells; (4) highly abundant
occurrence of cells. Scoring was done for both, intraepithelial and
stromal compartments (× 10 magnification) separately (25, 26).
Scoring for p16INK4a was done using a weighted score combining
percentage of stained cells and the intensity of staining. Staining
intensity was scored as 1+ (weak), 2+ (moderate), 3+ (intense).
The fraction of stained tumor cells was scored as 1 (0–25%), 2
(26–50%), 3 (51–75%) and 4 (75–100%). The final score was
generated by multiplication of both scores, leading to a score
ranging from 1 to 12.
We used the median value as cut-off to dichotomize the
cohort in patients either having a low (≤median) or high
(>median) score. Images were acquired with the Axio Scan
Z1 slide scanner using the ZEN software (Zeiss, Germany).
To minimize interobserver variability, two investigators without
knowledge of the clinicopathological and clinical data performed
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scoring. In cases of discrepancy, a final decision was made after
additional examination of the specimens.
Statistical Analysis
Differences between groups were assessed using Pearson’s Chi-
squared test for categorical variables, and the non-parametric
Wilcoxon rank sum test for continuous variables. Correlations
between continuous variables were assessed using the Spearman‘s
rank correlation coefficient. Survival times were calculated from
start of CRT to the date of respective events or last follow-
up. Locoregional control rate (LRC) was calculated using non-
complete response at first restaging or locoregional recurrence
after initial complete response as event. Disease-free survival
(DFS) was calculated using the date of diagnosis of locoregional
failure, distant metastases, or death of any cause. Distant
metastasis-free survival (DMFS) was calculated using the date of
diagnosis of distant metastases or death of any cause as event.
Overall survival (OS) was assessed with death of any cause as the
respective event. Survival differences were visualized by Kaplan-
Meier curves and the log-rank test was used for calculation. For
LRC, competing risk analysis was performed using the “cmprsk”
package with death as competing event.
Cut-off of CAR for DFS was calculated using the maximally
selected rank statistics, which calculate the most optimal cut-
off for a continuous variable regarding log-rank statistics using
an established algorithm (27). The Cox proportional hazard
model was used for univariate analysis to assess the influence
of CAR as a continuous variable, and with the dichotomized
CAR for multivariate analysis. Due to the skewness of CAR,
values were transformed using the binary logarithm, leading
to a broader distribution of data. Only factors found to
be significant in univariate analysis were included in the
multivariate one. Due to skewness of distribution, we used a
binary log transformation for inclusion in cox regression models.
The assumption of proportional hazard was tested by the scaled
Schoenfeld residuals. Due to the low number of events, we were
only able to conduct a multivariate analysis with a small set of
variables and with DFS as endpoint due to the larger number of
events (28). Statistical analysis was performed with R (Version
3.5) (29) using the packages maxstat, cmprsk, pROC (30) and
survminer. A p < 0.05 was considered significant.
RESULTS
Patient and Treatment Characteristics
Patient and treatment characteristics are summarized in Table 1.
Thirty of 125 patients (24%) were HIV-positive. Male gender
(median 0.11 vs. 0.04 for females, p < 0.01) and advanced
T-stage (0.15 for T3/4 vs. 0.04 for T1/2, p = 0.005) were
associated with a significantly higher CAR (Figure 1A), whereas
no significant association was noted for CAR with N-stage.
HIV-positive patients had a significantly higher CAR (median
0.12 vs. 0.06 for HIV-negative patients, p < 0.001). As 28
of 30 HIV-positive patients were male, we excluded them in
a subsequent analysis confirming a borderline significance for
higher CAR in HIV-negative male patients compared to female
patients (median 0.08 vs. 0.04, p = 0.053). As previous studies
TABLE 1 | Patients, tumor, and blood characteristics.
Median (range) or n (%)
Age, years 57 (34–84)
Sex Male 58 (46)
Female 67 (54)
HIV-Status Positive 30 (24)
Negative 95 (76)
T-Stage T1 28 (22)
T2 58 (46)
T3 32 (26)
T4 7 (6)
N-Stage N0 71 (57)
N+ 54 (43)
Grading G1 8 (6)
G2 84 (68)
G3 28 (22)
Unknown 5 (4)
Pretreatment blood chemistry
C reactive protein (mg/dl) 0.29 (0.02–21.78)
Albumin (g/dl) 4.40 (3.3–5.0)
CRP to Albumin Ratio (CAR) 0.063 (0.004–5.19)
Radiotherapy
RT modality 3D 44 (35)
IMRT 81 (65)
Total dose (Gy) 59.4 (50.4–64.8)
HIV, human immunodeficiency virus; Gy, Gray; RT, radiotherapy.
did not find a significant difference in the immune contexture of
HIV positive and negative patients (31), and also because HIV
positive patients do not have a worse prognosis under effective
antiretroviral therapy (32), we did not exclude HIV positive
patients in subsequent analysis. There was no correlation of
CAR with age (R = −0.076, p = 0.400) or body mass index (R
= −0.048, p= 0.600). Performance status was available in 100
of 126 patients (ECOG 0: 79, ECOG 1: 21) and there was no
correlation with CAR in this subgroup.
Univariate Analysis
We used maximally-selected rank statistics to estimate the best
cut-off for CAR to dichotomize the cohort of patients for the
endpoint DFS. The calculated CAR cut-off was 0.117, resulting
in 47 of 125 (37%) patients in the high CAR group. Using this
cut-off revealed a significant association of high CAR with worse
LRC (p = 0.005, using competing risk analysis with death as a
competing risk), DMFS (p = 0.010), DFS (p = 0.004), and OS
(p < 0.001) in univariate analysis (Figures 1B–D, Table 2). The
3 year LRC, DMFS, DFS, and OS rates were 91% vs. 72%, 93%
vs. 78%, 86% vs. 65%, and 95% vs. 72% for low vs. high CAR,
respectively. In a separate analysis, using the binary logarithm of
CAR as a continuous variable, we found a significant association
of CAR with worse DMFS (HR 1.31, p = 0.02), DFS (HR 1.19,
p = 0.040), and OS (HR 1.36, p < 0.001) in univariate analysis
(Table 2). Regarding established clinicopathologic parameters in
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FIGURE 1 | Patients with advanced T-stage and male gender had a significantly elevated CAR before initiation of treatment (A). Patients with high baseline CAR had a
worse LRC (B), DFS (C), and OS (D). CAR, CRP-albumin-ratio; LRC, locoregional control; DFS, disease-free survival; OS, overall survival.
TABLE 2 | Results of univariate cox regression analysis with calculated cut off and
binary log transformed CAR as continuous variable.
Dichotomized CAR Binary logarithm of CAR
HR 95% CI p-value HR 95% CI p-value
LRC 3.771 1.41–10.06 0.004 1.181 0.97–1.44 0.1
DMFS 4.065 1.25–13.21 0.010 1.311 1.05–1.64 0.02
DFS 3.162 1.40–7.16 0.004 1.191 1.01–1.41 0.04
OS 4.99 1.80–13.92 <0.001 1.364 1.13–1.64 <0.001
LRC, locoregional control; DMFS, distant-metastasis free survival; DFS, disease-free
survival; OS, overall survival; CAR, CRP-albumin-ratio; Significant values have been
marked in bold.
univariate analysis, cN+ was associated with worse LRC, DMFS,
and DFS, advanced T-stage was associated with worse DMFS
and male gender was associated with worse DMFS and DFS
(Supplementary Table S1).
In a next step, we created a combined score with CAR and
N-stage as these parameters are not correlated with each other,
termed N-CAR score. Only patients with both a high CAR
and cN+ were considered “N-CAR positive,” whereas all other
patients were scored as “N-CAR negative.” Overall, 26 of 125
patients (20.8%) were N-CAR positive. In univariate analysis the
combined N-CAR score was significantly prognostic for LRC
(p < 0.001, Figure 2A), DMFS (p < 0.001), DFS (p < 0.001,
Figure 2B), and OS (p = 0.001, Figure 2C). The 3 year LRC,
DMFS, DFS and OS rates were 91% vs. 58%, 93% vs. 66%, 86%
vs. 49% and 90% vs. 68% for negative vs. positive N-CAR score,
respectively. In an additional analysis, we tested our cut-off in
cN0 and cN+ patients, separately. In cN+ patients high CAR
remained significant for LRC (p = 0.04), DMFS (p = 0.04), DFS
(p = 0.04), and OS (p = 0.01), whereas there was no significant
difference in cN0 patients. Nevertheless, this has to be interpreted
cautiously due to the limited number of events in cN0 patients.
Multivariate Analysis
Due to the low number of events (LRC: 18, DMFS: 13,
DFS: 25), we conducted the multivariate analysis for DFS
and included CAR, gender and N-stage, as these factors were
significantly associated with worse DFS in univariate analysis.
In general, multivariate analysis with such a small number
of event need to be interpreted cautiously. Only lymph node
involvement remained a significant prognostic factor for adverse
DFS (Table 3). Multivariate models for LRC, DMFS, and OS
were also created but need to be interpreted cautiously due
to the low number of events. Nevertheless, N-stage was the
only factor that remained significant for LRC and DMFS,
whereas for OS CAR remained as the only significant factor
(Supplementary Table S2). As we found a correlation between
T-stage and CAR, we created another model including T-Stage,
CAR, and gender as variables. In this model, only CAR remained
as a significant prognostic factor (HR 2.71, 95% CI 1.04–7.22,
p= 0.042). Introduction of the N-CAR score into a multivariate
Frontiers in Oncology | www.frontiersin.org 4 November 2019 | Volume 9 | Article 1200
Martin et al. CRP to Albumin Ratio in Anal Cancer
FIGURE 2 | A combined score of N-stage and CAR was associated with worse LRC (A), DFS (B), and OS (C). Forest plot showing that N-CAR remained a significant
prognostic factor for DFS in a multivariate cox regression analysis with gender and T-stage (D). CAR, CRP-albumin-ratio; LRC, locoregional control; DFS, disease-free
survival.
TABLE 3 | Results of multivariate cox regression analysis DFS using dichotomized
CAR.
HR 95% CI p-value
DFS
CAR 2.13 0.91–4.99 0.082
N-stage (N+ vs. N0) 3.85 1.58–9.38 0.003
Gender (male vs. female) 2.18 0.91–5.21 0.079
DFS, disease-free survival; CAR, CRP-albumin-ratio; Significant values have been marked
in bold.
cox regression model together with T-stage and gender showed
that only the N-CAR score was significantly associated with
DFS (Figure 2D).
Correlation of CAR With CD8+ and
p16INK4a
We measured the infiltration of tumor tissue and peritumoral
stroma with CD8+ TIL in 78 patients with available tumor
specimens. A high intratumoral CD8 infiltration was associated
with a significantly lower CAR (p= 0.007), whereas there was no
statistically significant association between peritumoral CD8+
TIL and CAR (p = 0.9, Figure 3A). No correlation between
p16INK4a score and CARwas observed. High intratumoral CD8+
TIL were significantly associated with a better DFS in univariate
analysis (p = 0.03), whereas a high p16INK4a score showed a
trend toward better DFS (p = 0.06). Due to the smaller number
of events in this subset of patients, we conducted two separate
multivariate cox regression analysis for DFS combining one of
the established molecular markers with CAR in order to avoid
overfitting by including too many variables in the model (28). In
combination with CD8+ TIL no variable was significant for DFS
(Figure 3C), whereas CAR remained significant for DFS in the
model with the p16INK4a score (p= 0.023, Figure 3D).
DISCUSSION
Inflammation is one of the hallmarks of cancer (33) resulting
in an exhausted state of immune cells with subsequent
tumor immune escape and, thus, tumor progression (34).
Chronic inflammation can, via increased production of growth
factors, proangiogenic molecules and/or factors that modify the
extracellular matrix, promote invasive growth and metastasis
(35). CAR is a marker of inflammation and was first introduced
as a prognosticator for mortality of septic patients (20). Elevated
CRP-levels are associated with various inflammatory processes,
whereas decreased serum albumin levels are associated with
chronic diseases andmalnutrition and therefore can be a result of
chronic inflammatory processes that are known to play a central
role in carcinogenesis (36). Thus, in the context of malignant
diseases, CAR could act as a surrogate marker for prolonged
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FIGURE 3 | Strong intratumoral infiltration with CD8+ TIL was associated with elevated CAR at baseline, whereas there was no association between peritumoral TIL
and CAR (A). Exemplary stainings for high and low intratumoral and peritumoral infiltrations with CD8+ TIL (B). Forest plot of a multivariate cox regression model
including CAR and CD8 TIL (C) and CAR and p16 (D) for DFS. CAR, CRP-albumin-ratio; TIL, tumor-infiltrating-lymphocyte.
chronic inflammatory processes. Recently, Kinoshita et al. (37)
an association between CRP and serum albumin/malnutrition
with tumor stage and prognosis has been demonstrated in various
malignancies (38), but its role in ASCC remains unexplored.
In the present study, we evaluated CAR as a new biomarker
for patients with ASCC treated with definitive CRT. A high
baseline CAR was associated with larger tumors (T3/T4), male
gender, and HIV-positivity in the entire cohort. CAR was a
significant prognostic marker for LRC, DMFS, DFS, and OS
in univariate analysis. In multivariate analysis, only N-stage
remained significant for DFS. As CAR was not correlated with N-
stage in our analyses, we assessed a combined score of CAR and
positive lymph nodes, termed the N-CAR score. The predictive
power of this score was independent of T-stage and gender in our
cohort and could be of use in future trials.
In that context, a direct functional role for CRP in tumor
progression has been described in a breast cancer model, where
binding of CRP to integrin alpha2 subunits on tumor cells
fostered invasion (39). CRP is released by the liver upon IL-6
signaling that in turn promotes tumor progression. Interleukin
6 upregulates tumor-promoting M2 macrophages via either
STAT3 phosphorylation (40) or direct inhibition of apoptosis
and stimulation of proliferation, also mainly mediated by STAT3
(41). Intriguingly, an antitumor effect has been described for
CRP via inhibition of epithelial-mesenchymal transition and
tumor-promoting M2 macrophages in preclinical studies (42,
43). However, at present one cannot rule out that CRP has no
direct effect on tumors but rather displays a down-stream effect
of IL-6 mediated tumor progression.
In a subset of patients with available pretreatment tumor
tissue, a strong intratumoral infiltration with CD8+ TIL was
associated with lower CAR whereas no association of CAR
with p16INK4a immunohistochemistry as surrogate parameter for
HPV infection was noted. This is in line with the notion that
chronic inflammation can lead to inhibition of CD8+ TIL by
various mechanisms including expansion of regulatory T-cells
or upregulation of immune checkpoints like programmed death
ligand 1 (PD-L1) (36). Interestingly, in renal cell carcinoma
higher CRP was associated with a stronger infiltration with
CD8+, FoxP3+ and CD163+ cells and subsequently with
worse prognosis (44). FoxP3+ and CD163+ cells are generally
regarded to be associated with immunosuppression and chronic
inflammation (45, 46) and the combination with a rise in CD8+
infiltration and worse prognosis may indicate that these CD8
cells are mainly exhausted. While HPV status is an established
prognostic parameter in ASCC (10) we could not find an
association of CAR with p16INK4a.
There is no consensus regarding the optimal cut-off for
CAR. Previous studies have estimated the optimal cut-off
using approaches similar to ours leading to a variety of
cut-offs (Table 4). The large variability in the range of cut-
off values among the various studies could be explained by
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TABLE 4 | CAR cut-offs reported in the literature.
Author Tumor entity Cut-off
Kuboki et al. (21) HNSCC 0.32
Guo et al. (22) Bladder 0.2
Otowa et al. (23) Esophageal SCC 0.048
Liu et al. (24) PDAC 0.18
Liu et al. (47) Ovarian Cancer 0.68
Wu et al. (48) PDAC 0.54
Zhou et al. (49) SCLC 0.441
Kinoshita et al. (37) HCC 0.037
Our Data ASCC 0.117
HNSCC, head and neck squamous cell carcinoma; SCC, squamous cell carcinoma;
PDAC, pancreatic ductal.adenocarcinoma; SCLC, small cell lung cancer; HCC,
hepatocellular carcinoma; ASCC, anal squamous cell carcinoma.
differences in tumor burden and degree of hypoalbuminemia. In
pancreatic cancer, two studies reported different cut-offs, while
the proportion of patients with metastatic disease was similar
in both cohorts (24, 48). In our series in non-metastatic ASCC,
only a small variation in albumin levels was observed, indicated
by a small standard deviation of 0.35. Thus, the range of CAR
values in our cohort were mainly a result of baseline CRP levels.
Nevertheless, more variation in albumin levels may be detected
in other cohorts, leading to the need for further exploration of
this marker (50). Of note, we also repeated our analysis using
the cut-offs in other squamous cell carcinomas (see Table 4)
and found an association with worse OS using both cut-offs
(Supplementary Table S3).
The prognosis of ASCC following primary CRT varies
considerably. Patients with early-stage T1-2 N0 disease, have
favorable prognosis with a 3 year DFS between 80 and 90% after
CRT, and such a subgroup of these patients are often overtreated
with late gastrointestinal toxicity that adversely impacts quality
of life (5). In contrast, the 3 year DFS is ∼60% in patients with
cT3-4 and /or cN+ tumors (Stage IIb-IIIC), where local and/or
distant failures commonly occur (7). Accordingly, escalation
strategies should be explored in these patients. In that context,
CAR should be further explored as a biomarker in future trials.
Such trials could involve immune modifying agents alone or in
combination with CRT, with first data in the metastatic setting
showing good tolerance and promising results (51, 52). Another
cheap available potential predictive biomarkers are baseline
hemoglobin levels (53).
There are several limitations to our study. First, the
retrospective nature of our analysis could lead to selection bias
and information on well-established molecular markers CD8+
TILs and p16INK4a was only available for a subgroup. Second, the
prognostic value of CAR as a biomarker needs to be validated
in an independent cohort of patients with ASCC treated with
standard CRT. Third, the optimal cut-off for CAR to stratify
patients into good and poor prognostic groups needs to be
established. Fourth, smoking status was not available for analysis.
Fifth, performance status was only available in 100 of 126 patients
and thus was not included in the analysis. Sixth, the relatively
small sample size.
In conclusion, CAR is a cheap and routinely available
biomarker that may be predictive of clinical outcome after
CRT in ASCC. Validation in an independent cohort of patients
is still needed. Further studies should aim to validate the
potential of CAR as a prognostic marker in larger, preferably
prospective ASCC cohorts, to help guide personalized future
treatment strategies.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Ethics committee Goethe University Frankfurt
University Hospital Frankfurt. Written informed consent for
participation was not required for this study in accordance with
the national legislation and the institutional requirements.
AUTHOR CONTRIBUTIONS
DM, FR, CR, and EF contributed to conception and design
of the study and wrote sections of the manuscript. DM,
FR, and PB organized the database. DM and RW performed
immunohistochemical analysis. DM performed the statistical
analysis and wrote the first draft of the manuscript. All authors
contributed to manuscript revision, read, and approved the
submitted version.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fonc.
2019.01200/full#supplementary-material
REFERENCES
1. Bouvier A-M, Belot A, Manfredi S, Jooste V, Uhry Z, Faivre J, et al. Trends
of incidence and survival in squamous-cell carcinoma of the anal canal
in France: a population-based study. Eur J Cancer Prev. (2016) 25:182–7.
doi: 10.1097/CEJ.0000000000000163
2. Guren MG, Aagnes B, Nygård M, Dahl O, Møller B. Rising incidence and
improved survival of anal squamous cell carcinoma in Norway, 1987-2016.
Clin Colorectal Cancer. (2018) 18:e96–103. doi: 10.1016/j.clcc.2018.10.001
3. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS,
Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without
maintenance chemotherapy for treatment of squamous-cell carcinoma of the
anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet
Oncol. (2013) 14:516–24. doi: 10.1016/S1470-2045(13)70086-X
4. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson
AB, et al. Long-term update of US GI intergroup RTOG 98-11 phase
III trial for anal carcinoma: survival, relapse, and colostomy failure
with concurrent chemoradiation involving fluorouracil/mitomycin
Frontiers in Oncology | www.frontiersin.org 7 November 2019 | Volume 9 | Article 1200
Martin et al. CRP to Albumin Ratio in Anal Cancer
versus fluorouracil/cisplatin. J Clin Oncol. (2012) 30:4344–51.
doi: 10.1200/JCO.2012.43.8085
5. Pan YB, Maeda Y, Wilson A, Glynne-Jones R, Vaizey CJ. Late gastrointestinal
toxicity after radiotherapy for anal cancer: a systematic literature review. Acta
Oncol. (2018) 57:1427–37. doi: 10.1080/0284186X.2018.1503713
6. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR,
et al. Prognostic factors derived from a prospective database dictate clinical
biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. (2010)
116:4007–13. doi: 10.1002/cncr.25188
7. Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson
AB, et al. Anal carcinoma: impact of TN category of disease on survival,
disease relapse, and colostomy failure in US Gastrointestinal Intergroup
RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. (2013) 87:638–45.
doi: 10.1016/j.ijrobp.2013.07.035
8. Balermpas P, Martin D, Wieland U, Rave-Fränk M, Strebhardt K,
Rödel C, et al. Human papilloma virus load and PD-1/PD-L1, CD8+
and FOXP3 in anal cancer patients treated with chemoradiotherapy:
rationale for immunotherapy. OncoImmunology. (2017) 6:e1288331.
doi: 10.1080/2162402X.2017.1288331
9. Rödel F, Wieland U, Fraunholz I, Kitz J, Rave-Fränk M, Wolff HA, et al.
Human papillomavirus DNA load and p16 INK4a expression predict for
local control in patients with anal squamous cell carcinoma treated with
chemoradiotherapy: HPV16 DNA and p16 INK4a Expression. Int J Cancer.
(2014) 136:278–88. doi: 10.1002/ijc.28979
10. Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, Høgdall E, Geertsen
PF, Havsteen H. Human papillomavirus genotyping and p16 expression as
prognostic factors for patients with American Joint Committee on Cancer
stages I to III carcinoma of the anal canal. J Clin Oncol. (2014) 32:1812–17.
doi: 10.1200/JCO.2013.52.3464
11. Gilbert DC, Serup-Hansen E, Linnemann D, Høgdall E, Bailey C, Summers J,
et al. Tumour-infiltrating lymphocyte scores effectively stratify outcomes over
and above p16 post chemo-radiotherapy in anal cancer. Br J Cancer. (2016)
114:134–7. doi: 10.1038/bjc.2015.448
12. Schernberg A, Escande A, Rivin Del Campo E, Ducreux M, Nguyen F, Goere
D, et al. Leukocytosis and neutrophilia predicts outcome in anal cancer.
Radiother Oncol. (2017) 122:137–45. doi: 10.1016/j.radonc.2016.12.009
13. Toh E, Wilson J, Sebag-Montefiore D, Botterill I. Neutrophil:lymphocyte ratio
as a simple and novel biomarker for prediction of locoregional recurrence
after chemoradiotherapy for squamous cell carcinoma of the anus. Colorectal
Dis. (2014) 16:O90–7. doi: 10.1111/codi.12467
14. Martin D, Rödel F, Winkelmann R, Balermpas P, Rödel C, Fokas E. Peripheral
leukocytosis is inversely correlated with intratumoral CD8+ T-cell infiltration
and associated with worse outcome after chemoradiotherapy in anal cancer.
Front Immunol. (2017) 8:1225. doi: 10.3389/fimmu.2017.01225
15. Schernberg A, Moureau-Zabotto L, Rivin Del Campo E, Escande A, Ducreux
M, Nguyen F, et al. Leukocytosis and neutrophilia predict outcome in
locally advanced esophageal cancer treated with definitive chemoradiation.
Oncotarget. (2017) 8:11579–88. doi: 10.18632/oncotarget.14584
16. Mabuchi S, Matsumoto Y, Isohashi F, Yoshioka Y, Ohashi H, Morii
E, et al. Pretreatment leukocytosis is an indicator of poor prognosis
in patients with cervical cancer. Gynecol Oncol. (2011) 122:25–32.
doi: 10.1016/j.ygyno.2011.03.037
17. Thompson D, Pepys MB, Wood SP. The physiological structure of human
C-reactive protein and its complex with phosphocholine. Structure. (1999)
7:169–77. doi: 10.1016/S0969-2126(99)80023-9
18. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein
and the risk of incident colorectal cancer. JAMA. (2004) 291:585–90.
doi: 10.1001/jama.291.5.585
19. Van Cutsem E, Arends J. The causes and consequences of cancer-
associated malnutrition. Eur J Oncol Nurs. (2005) 9(Suppl 2):S51–63.
doi: 10.1016/j.ejon.2005.09.007
20. Ranzani OT, Zampieri FG, Forte DN, Azevedo LCP, Park M. C-reactive
protein/albumin ratio predicts 90-day mortality of septic patients. PLoS ONE.
(2013) 8:e59321. doi: 10.1371/journal.pone.0059321
21. Kuboki A, Kanaya H, Nakayama T, Konno W, Goto K, Nakajima I, et al.
Prognostic value of C-reactive protein/albumin ratio for patients with
hypopharyngeal and laryngeal cancer undergoing invasive surgery involving
laryngectomy. Head Neck. (2018) 41:1342–50. doi: 10.1002/hed.25565
22. Guo Y, Cai K, Mao S, Zhang J, Wang L, Zhang Z, et al. Preoperative C-reactive
protein/albumin ratio is a significant predictor of survival in bladder cancer
patients after radical cystectomy: a retrospective study. Cancer Manag Res.
(2018) 10:4789–804. doi: 10.2147/CMAR.S180301
23. Otowa Y, Nakamura T, Yamamoto M, Kanaji S, Matsuda Y, Matsuda T, et al.
C-reactive protein to albumin ratio is a prognostic factor for patients with
cStage II/III esophageal squamous cell cancer. Dis Esophagus. (2017) 30:1–5.
doi: 10.1093/dote/dox107
24. Liu Z, Jin K, GuoM, Long J, Liu L, Liu C, et al. Prognostic value of the CRP/Alb
Ratio, a novel inflammation-based score in pancreatic cancer.Ann Surg Oncol.
(2017) 24:561–8. doi: 10.1245/s10434-016-5579-3
25. Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Öberg Å, Rutegård
J, et al. Colorectal cancer prognosis depends on T-cell infiltration and
molecular characteristics of the tumor. Mod Pathol. (2011) 24:671–82.
doi: 10.1038/modpathol.2010.234
26. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al.
Tumor-associated lymphocytes as an independent predictor of response to
neoadjuvant chemotherapy in breast cancer. J Clin Oncol. (2010) 28:105–13.
doi: 10.1200/JCO.2009.23.7370
27. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics.
(1992) 48:73–85. doi: 10.2307/2532740
28. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation
study of the number of events per variable in logistic regression analysis. J
Clin Epidemiol. (1996) 49:1373–9. doi: 10.1016/S0895-4356(96)00236-3
29. R Development Core Team. R: A Language and Environment for Statistical
Computing. Vienna, Austria: R Foundation for Statistical Computing (2008).
Available online at: http://www.r-project.org
30. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC:
an open-source package for R and S+ to analyze and compare ROC curves.
BMC Bioinformatics. (2011) 12:77. doi: 10.1186/1471-2105-12-77
31. Yanik EL, Kaunitz GJ, Cottrell TR, Succaria F, McMiller TL, Ascierto ML, et al.
Association of HIV status with local immune response to anal squamous cell
carcinoma: implications for immunotherapy. JAMA Oncol. (2017) 3:974–8.
doi: 10.1001/jamaoncol.2017.0115
32. White EC, Khodayari B, Erickson KT, Lien WW, Hwang-Graziano J, Rao AR.
Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-
negative patients with squamous cell carcinoma of the anal canal. Am J Clin
Oncol. (2014) 40:386–92. doi: 10.1097/COC.0000000000000172
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
(2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
34. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer
immunosurveillance and immunoediting. Immunity. (2004) 21:137–48.
doi: 10.1016/j.immuni.2004.07.017
35. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer.
Cell. (2010) 140:883–99. doi: 10.1016/j.cell.2010.01.025
36. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting
chronic inflammation: a magic bullet? Science. (2013) 339:286–91.
doi: 10.1126/science.1232227
37. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The C-
reactive protein/albumin ratio, a novel inflammation-based prognostic score,
predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol.
(2015) 22:803–10. doi: 10.1245/s10434-014-4048-0
38. Yu JM, Yang M, Xu HX, Li W, Fu ZM, Lin Y, et al. Association between
serum C-reactive protein concentration and nutritional status of malignant
tumor patients. Nutr Cancer. (2018) 71:240–5. doi: 10.1080/01635581.2018.15
24019
39. Kim E-S, Kim SY, Koh M, Lee H-M, Kim K, Jung J, et al. C-reactive
protein binds to integrin α2 and Fcγ receptor I, leading to breast
cell adhesion and breast cancer progression. Oncogene. (2018) 37:28–38.
doi: 10.1038/onc.2017.298
40. Fu X-L, Duan W, Su C-Y, Mao F-Y, Lv Y-P, Teng Y-S, et al. Interleukin 6
induces M2 macrophage differentiation by STAT3 activation that correlates
with gastric cancer progression. Cancer Immunol Immunother. (2017)
66:1597–608. doi: 10.1007/s00262-017-2052-5
41. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete
the link. Cancer Cell. (2009) 15:79–80. doi: 10.1016/j.ccr.2009.01.009
42. Kudo S, Saito H, Motoyama S, Sasaki T, Imai K, Konno H, et al.
C-reactive protein inhibits expression of N-cadherin and ZEB-1 in
Frontiers in Oncology | www.frontiersin.org 8 November 2019 | Volume 9 | Article 1200
Martin et al. CRP to Albumin Ratio in Anal Cancer
murine colon adenocarcinoma. Tumour Biol. (2015) 36:7035–43.
doi: 10.1007/s13277-015-3414-2
43. Kuribayashi K, Motoyama S, Sasaki T, Sato Y, Yoshino K, Wakita A, et al.
C-reactive protein reduces the relative number of tumor-associated M2
macrophages and intratumoral angiogenesis in mice. Tohoku J Exp Med.
(2014) 233:249–55. doi: 10.1620/tjem.233.249
44. Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S, et al.
Higher serum C-reactive protein level represents the immunosuppressive
tumor microenvironment in patients with clear cell renal cell carcinoma. Clin
Genitourin Cancer. (2018) 16:e1151–8. doi: 10.1016/j.clgc.2018.07.027
45. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+
tumor-infiltrating lymphocytes in cancer: a critical review of the literature.
Clin Cancer Res. (2012) 18:3022–9. doi: 10.1158/1078-0432.CCR-11-3216
46. Balermpas P, Rödel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S,
et al. Head and neck cancer relapse after chemoradiotherapy correlates with
CD163+ macrophages in primary tumour and CD11b+ myeloid cells in
recurrences. Br J Cancer. (2014) 111:1509–18. doi: 10.1038/bjc.2014.446
47. Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L, et al. The
prognostic value of the preoperative c-reactive protein/albumin ratio in
ovarian cancer. BMC Cancer. (2017) 17:285. doi: 10.1186/s12885-017-
3220-x
48. Wu M, Guo J, Guo L, Zuo Q. The C-reactive protein/albumin ratio predicts
overall survival of patients with advanced pancreatic cancer. Tumour Biol.
(2016) 37:12525–33. doi: 10.1007/s13277-016-5122-y
49. Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T, et al. Ratio of C-reactive
protein/albumin is an inflammatory prognostic score for predicting overall
survival of patients with small-cell lung cancer. Sci Rep. (2015) 5:10481.
doi: 10.1038/srep10481
50. Hu W-H, Cajas-Monson LC, Eisenstein S, Parry L, Cosman B, Ramamoorthy
S. Preoperative malnutrition assessments as predictors of postoperative
mortality andmorbidity in colorectal cancer: an analysis of ACS-NSQIP.Nutr
J. (2015) 14:91. doi: 10.1186/s12937-015-0081-5
51. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ,
Cohen RB, et al. Safety and antitumor activity of the anti-PD-1 antibody
pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann
Oncol. (2017) 28:1036–41. doi: 10.1093/annonc/mdx029
52. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al.
Nivolumab for previously treated unresectable metastatic anal cancer
(NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. (2017)
18:446–53. doi: 10.1016/S1470-2045(17)30104-3
53. Franco P, Montagnani F, Arcadipane F, Casadei C, Andrikou K, Martini
S, et al. The prognostic role of hemoglobin levels in patients undergoing
concurrent chemo-radiation for anal cancer. Radiat Oncol. (2018) 13:83.
doi: 10.1186/s13014-018-1035-9
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Martin, Rödel, Balermpas, Winkelmann, Fokas and Rödel. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Oncology | www.frontiersin.org 9 November 2019 | Volume 9 | Article 1200
